AstraZeneca’s surovatamig received EU orphan drug designation from the European Medicines Agency (EMA) on 20 April 2026 for the treatment of large B-cell lymphoma (LBCL), under designation number EU/3/26/3224. The molecule, also known by its development code AZD0486 and originally designated TNB-486 by its originator Teneobio, is a bispecific T-cell engager (TCE) targeting CD19 on malignant B-cells and CD3 on T-cells.
In the EU, orphan drug designation provides a 10-year period of marketing exclusivity following product approval, along with incentives including protocol assistance from the EMA and direct access to the centralized authorization procedure.
Surovatamig is currently in active clinical development across two recruiting trials. The Phase II SOUNDTRACK-B study (NCT06526793) evaluates surovatamig as monotherapy in participants with relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL), including large B-cell lymphoma. In parallel, a Phase I/II master protocol (NCT06564038) examines surovatamig as monotherapy or in combination with other anti-cancer agents across a broader range of mature B-cell malignancies including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle-cell lymphoma. Clinical activity data in r/r diffuse large B-cell lymphoma (DLBCL) were presented at ASCO 2025, representing the first substantive public readout for the program in this setting.
The molecule’s mechanistic distinction within the CD19×CD3 bispecific class lies in its low-affinity CD3-binding arm, engineered to reduce cytokine release syndrome (CRS) risk — a dose-limiting toxicity associated with earlier T-cell engagers — while preserving anti-tumor activity. This structural feature was central to Teneobio’s UniAb platform, which AstraZeneca acquired in October 2021 for approximately USD 1.27 billion, with around USD 900 million paid upfront and up to USD 370 million in milestones. At the time of acquisition, TNB-486 was in early clinical development and identified as a lead hematology asset.
The CD19 target also differentiates surovatamig from the approved CD20×CD3 bispecific antibodies in LBCL — including mosunetuzumab (Roche) and epcoritamab (AbbVie/Genmab) — which engage a distinct surface antigen. Because CD19 is expressed on B-cells independently of CD20 status, a CD19-directed approach may retain activity in patients who have relapsed following CD20-directed therapy or CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy, though clinical data in these specific populations from the current trials have not yet been publicly reported in full.
Surovatamig holds no marketing authorization in any jurisdiction and remains investigational. The EMA orphan designation does not constitute approval for clinical use; all medicines designated as orphan medicines in the EU must obtain a full marketing authorization before they can be made available to patients.